These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 26438119)

  • 1. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
    Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
    J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
    Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
    Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
    Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
    Ajani JA; Fodor MB; Tjulandin SA; Moiseyenko VM; Chao Y; Cabral Filho S; Majlis A; Assadourian S; Van Cutsem E
    J Clin Oncol; 2005 Aug; 23(24):5660-7. PubMed ID: 16110025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
    Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
    Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY
    Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
    Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
    Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
    Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
    Deleporte A; Van den Eynde M; Forget F; Holbrechts S; Delaunoit T; Houbiers G; Kalantari HR; Laurent S; Vanderstraeten E; De Man M; Vergauwe P; Clausse M; Van Der Auwera J; D'Hondt L; Pierre P; Ghillemijn B; Covas A; Paesmans M; Ameye L; Awada A; Sclafani F; Hendlisz A
    Cancer Med; 2021 Jul; 10(13):4366-4374. PubMed ID: 34057299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna.
    Bojic M; Pluschnig U; Zacherl J; Thallinger CM; Ba-Ssalamah A; Maresch J; Datler P; Schoppmann SF; Hejna M
    Anticancer Res; 2011 Jun; 31(6):2379-82. PubMed ID: 21737668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Gürler F; Güven DC; Aydemir E; Sütçüoğlu O; İnci BK; Arık Z; Yalçın Ş; Özdemir N; Özet A; Yazıcı O
    Turk J Med Sci; 2022 Oct; 52(5):1559-1568. PubMed ID: 36422493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
    Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
    Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
    Zaanan A; Samalin E; Aparicio T; Bouche O; Laurent-Puig P; Manfredi S; Michel P; Monterymard C; Moreau M; Rougier P; Tougeron D; Taieb J; Louvet C
    Dig Liver Dis; 2018 Apr; 50(4):408-410. PubMed ID: 29409778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.